Equillium Inc (EQ)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.23-3.15%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Equillium Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.056
Annual ending 2026-12-31
Revenue	—	15.58M
EPS	—	-0.206
Annual ending 2027-12-31
Revenue	—	16.52M
EPS	—	-0.232

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Progress in developing EQ504 using private placement funds	The company has raised money from a private placement.	Intact	Development of EQ504 stalls or funds are insufficient	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Cash and equivalents sufficient to fund operations into 2029	Equillium is working to fund operations through 2029.	Intact	Cash falls below levels needed to fund operations into 2029	Cash and cash equivalents: $57.164M FY2026-Q2; GAAP. Published target: Sufficient cash to fund operations through 2029. Target period is not explicitly aligned with this observation. Source date unavailable57,164,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Control losses and improve cash flow	A supporting condition in Equillium Inc's published investment case. The stated target is Reduce net loss and improve cash flow toward breakeven.	Improving	Losses worsen or cash flow deteriorates further	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.23

$-0.25 → $-0.23 · observed estimates

FY2027 revenue$0.02B

$0.02B → $0.02B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.25	$16,524,000	7 / 8
2026-07-25	$-0.25	$16,524,000	7 / 8
2026-07-26	$-0.25	$16,524,000	7 / 9
2026-07-27	$-0.25	$16,524,000	7 / 9
2026-07-28	$-0.25	$16,524,000	7 / 9
2026-07-29	$-0.25	$16,524,000	7 / 9
2026-07-30	$-0.25	$16,524,000	7 / 9
2026-07-31	$-0.27	$0	7 / 9
2026-08-01	$-0.25	$16,524,000	7 / 9
2026-08-02	$-0.27	$0	7 / 9
2026-08-03	$-0.25	$16,524,000	7 / 9
2026-08-04	$-0.25	$16,524,000	7 / 9
2026-08-05	$-0.27	$0	7 / 9
2026-08-06	$-0.25	$16,524,000	7 / 9
2026-08-07	$-0.25	$16,524,000	7 / 9
2026-08-08	$-0.27	$0	7 / 9
2026-08-09	$-0.27	$0	7 / 9
2026-08-10	$-0.27	$0	7 / 9
2026-08-11	$-0.27	$0	7 / 9
2026-08-12	$-0.27	$0	7 / 9
2026-08-13	$-0.27	$0	7 / 9
2026-08-14	$-0.25	$16,524,000	7 / 9
2026-08-15	$-0.25	$16,524,000	7 / 9
2026-08-16	$-0.25	$16,524,000	7 / 9
2026-08-17	$-0.25	$16,524,000	7 / 9
2026-08-18	$-0.25	$16,524,000	7 / 9
2026-08-19	$-0.25	$16,524,000	7 / 9
2026-08-20	$-0.23	$16,524,000	7 / 9
2026-08-21	$-0.23	$16,524,000	7 / 9
2026-08-22	$-0.23	$16,524,000	7 / 9
2026-08-23	$-0.23	$16,524,000	7 / 9
2026-08-24	$-0.23	$16,524,000	7 / 9
2026-08-25	$-0.23	$16,524,000	7 / 9
2026-08-26	$-0.23	$16,524,000	7 / 9
2026-08-27	$-0.23	$16,524,000	7 / 9
2026-08-28	$-0.23	$16,524,000	7 / 9
2026-08-29	$-0.23	$16,524,000	7 / 9
2026-08-30	$-0.23	$16,524,000	7 / 9
2026-08-31	$-0.23	$16,524,000	7 / 9
2026-09-01	$-0.23	$16,524,000	7 / 9
2026-09-02	$-0.23	$16,524,000	7 / 9
2026-09-03	$-0.23	$16,524,000	7 / 9
2026-09-04	$-0.23	$16,524,000	7 / 9
2026-09-05	$-0.23	$16,524,000	7 / 9
2026-09-06	$-0.23	$16,524,000	7 / 9
2026-09-07	$-0.23	$16,524,000	7 / 9
2026-09-08	$-0.23	$16,524,000	7 / 9
2026-09-09	$-0.23	$16,524,000	7 / 9
2026-09-10	$-0.23	$16,524,000	7 / 9
2026-09-11	$-0.23	$16,524,000	7 / 9
2026-09-12	$-0.23	$16,524,000	7 / 9
2026-09-13	$-0.23	$16,524,000	7 / 9
2026-09-14	$-0.23	$16,524,000	7 / 9
2026-09-15	$-0.23	$16,524,000	7 / 9
2026-09-16	$-0.23	$16,524,000	7 / 9
2026-09-17	$-0.23	$16,524,000	7 / 9
2026-09-18	$-0.23	$16,524,000	7 / 9
2026-09-19	$-0.23	$16,524,000	7 / 9
2026-09-20	$-0.23	$16,524,000	7 / 9
2026-09-21	$-0.23	$16,524,000	7 / 9
2026-09-22	$-0.23	$16,524,000	7 / 9
2026-09-23	$-0.23	$16,524,000	7 / 9
2026-09-24	$-0.23	$16,524,000	7 / 9
2026-09-25	$-0.23	$16,524,000	7 / 9
2026-09-26	$-0.23	$16,524,000	7 / 9
2026-09-27	$-0.23	$16,524,000	7 / 9
2026-09-28	$-0.23	$16,524,000	7 / 9
2026-09-29	$-0.23	$16,524,000	7 / 9
2026-09-30	$-0.23	$16,524,000	7 / 9
2026-10-01	$-0.23	$16,524,000	7 / 9
2026-10-02	$-0.23	$16,524,000	7 / 9
2026-10-03	$-0.23	$16,524,000	7 / 9
2026-10-04	$-0.23	$16,524,000	7 / 9
2026-10-05	$-0.23	$16,524,000	7 / 9
2026-10-06	$-0.23	$16,524,000	7 / 9
2026-10-07	$-0.23	$16,524,000	7 / 9
2026-10-08	$-0.23	$16,524,000	7 / 9
2026-10-09	$-0.23	$16,524,000	7 / 9
2026-10-10	$-0.23	$16,524,000	7 / 9
2026-10-11	$-0.23	$16,524,000	7 / 9
2026-10-12	$-0.23	$16,524,000	7 / 9
2026-10-13	$-0.23	$16,524,000	7 / 9
2026-10-14	$-0.23	$16,524,000	7 / 9
2026-10-15	$-0.23	$16,524,000	7 / 9
2026-10-16	$-0.23	$16,524,000	7 / 9
2026-10-17	$-0.23	$16,524,000	7 / 9
2026-10-18	$-0.23	$16,524,000	7 / 9
2026-10-19	$-0.23	$16,524,000	7 / 9
2026-10-20	$-0.23	$16,524,000	7 / 9
2026-10-21	$-0.23	$16,524,000	7 / 9
2026-10-22	$-0.23	$16,524,000	7 / 9
2026-10-23	$-0.23	$16,524,000	7 / 9
2026-10-24	$-0.23	$16,524,000	7 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	1
2026-06-01	8	0
2026-07-01	9	0
2026-08-01	9	0
2026-09-01	9	0
2026-10-01	9	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Progress in developing EQ504 using private placement fundsDirect metric needs a verified mapping
Cash and equivalents sufficient to fund operations into 2029Cash and cash equivalents: $57.164M
Control losses and improve cash flowDirect metric needs a verified mapping

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.3%Typical daily move · historical

Downside history

-62.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Equillium Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not a proven compounder: EQ is loss-making, recent financial performance is weak, and risk is high. The long-term thesis is in a watch state, with management still focused on EQ504, EQ302, and extending the cash runway.

What's priced into Equillium Inc

The valuation evidence is mixed: EQ is tagged as cheap versus peers, but the model also shows a 12% peer premium and an expectations gap of -0.35. Model confidence is low, so the evidence does not support a firm view of what expectations are already reflected in the valuation.

What the fundamentals likely do

Near term, results may remain uneven: EQ missed earnings in May and beat in August, while performance remains well below its industry cohort. Cash declined from $61.3 million in the first quarter to $57.2 million in the second, though management says it can fund operations into 2029; EQ504's planned Phase 1 study and EQ302's early development are progress points, but both priorities remain mixed. The next earnings report carries elevated miss risk, and a recent litigation filing adds uncertainty.

What Equillium Inc hinges on

The multi-year view hinges on EQ504 reaching its planned study milestones and EQ302 advancing, while the company maintains enough cash to fund operations. Near term, a guidance cut or further weakening in jobs data could weigh on the business outlook, while continued strength among sector bellwethers could support the sector backdrop.